Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 16/20 | 0.80 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652768 | 0.89 | MAPK1 (1.00) | MAPK1CREBBPJAK3 | |
| SCHEMBL15653387 | 0.87 | MAPK1 (0.75) | MAPK1CREBBPJAK3 | |
| SCHEMBL15653554 | 0.86 | MAPK1 (0.76) | MAPK1ALK | |
| SCHEMBL21592513 | 0.83 | MAPK1 (0.69) | MAPK1CREBBPJAK3MAP4K1 | |
| SCHEMBL10141887 | 0.82 | MAPK1 (0.68) | MAPK1CREBBPJAK3MAP4K1 | |
| SCHEMBL19657316 | 0.81 | MAPK1 (0.67) | MAPK1CREBBPALKJAK3 | |
| SCHEMBL2731192 | 0.80 | MAPK1 (0.56) | MAPK1ALK | |
| SCHEMBL19657749 | 0.79 | MAPK1 (0.64) | MAPK1CREBBPALKJAK3 | |
| SCHEMBL21592460 | 0.79 | MAP4K1 (0.67) | MAPK1CREBBPMAP4K1 | |
| SCHEMBL2733285 | 0.79 | MAPK1 (0.59) | MAPK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529952-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | claimed |
| WO-2010015803-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R & D MANAGEMENT CO. LTD (JP) | 2010-02-11 | — | — | WO | claimed |
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| EP-2324021-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015803-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R & D MANAGEMENT CO. LTD (JP) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | DAPK1, DAPK2, DAPK3 | MAPK1 21/4885CREBBP 359/4885ALK 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.